We are live on ! Find out more
AAA

Affinity Asset Advisors Portfolio holdings

AUM $2.21B
1-Year Est. Return 431.26%
This Fund
S&P 500
This Quarter Est. Return
+1.53%
1 Year Est. Return
+431.26%
3 Year Est. Return
+1,487.3%
5 Year Est. Return
+3,318.95%
10 Year Est. Return
–
AUM
$275M
AUM Growth
-$121M
Cap. Flow
+$698K
Cap. Flow %
0.25%
Top 10 Hldgs %
43.72%
Holding
87
New
14
Increased
18
Reduced
10
Closed
32

Top Buys

Rank Stock Value
1
SWTX
SpringWorks Therapeutics
SWTX
+$11.4M
2
PTGX icon
Protagonist Therapeutics
PTGX
+$7.62M
3
MORF
Morphic Holding, Inc. Common Stock
MORF
+$6.89M
4
KDNY
Chinook Therapeutics, Inc. Common Stock
KDNY
+$6.84M
5
ARNA
Arena Pharmaceuticals Inc
ARNA
+$6.59M

Top Sells

Rank Stock Value
1
OCUL icon
Ocular Therapeutix
OCUL
+$7.5M
2
BBIO icon
BridgeBio Pharma
BBIO
+$6.79M
3
XLRN
Acceleron Pharma
XLRN
+$6.08M
4
ASND icon
Ascendis Pharma A/S
ASND
+$5.72M
5
TVTX icon
Travere Therapeutics
TVTX
+$4.22M

Sector Composition

Rank Sector Weight
1 Healthcare 74.45%
2 Miscellaneous 20.02%
3 Financials 4.97%
4 Industrials 0.56%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
MORF
1
DELISTED
Morphic Holding, Inc. Common Stock
MORF
$18.9M 6.87%
399,302
+128,547
+47% +$6.89M
SWTX
2
DELISTED
SpringWorks Therapeutics
SWTX
$18.5M 6.72%
298,545
+172,532
+137% +$11.4M
FLNA
3
PUT
Filana Therapeutics
FLNA
$39.6M
$15.3M 5.55%
350,000
+275,000
+367% +$14.4M
VINC
4
DELISTED
Vincerx Pharma, Inc. Common Stock
VINC
$11.6M 4.2%
56,768
+6,518
+13% +$1.63M
NARI
5
DELISTED
Inari Medical, Inc. Common Stock
NARI
$11.4M 4.14%
125,000
-10,000
-7% -$857K
ZNTL icon
6
Zentalis Pharmaceuticals
ZNTL
$378M
$9.88M 3.59%
117,500
+40,000
+52% +$3.1M
ARNA
7
DELISTED
Arena Pharmaceuticals Inc
ARNA
$9.29M 3.38%
+100,000
New +$6.59M
KDNY
8
DELISTED
Chinook Therapeutics, Inc. Common Stock
KDNY
$9.05M 3.29%
555,155
+480,814
+647% +$6.84M
PTGX icon
9
Protagonist Therapeutics
PTGX
$9.43B
$8.25M 2.99%
+241,119
New +$7.62M
BBIO icon
10
BridgeBio Pharma
BBIO
$14.6B
$8.24M 2.99%
494,046
-160,389
-25% -$6.79M
KURA icon
11
Kura Oncology
KURA
$1.18B
$7.84M 2.85%
560,000
+30,000
+6% +$486K
MRNA icon
12
PUT
Moderna
MRNA
$58.1B
$7.62M 2.77%
+30,000
New +$8.77M
CERE
13
DELISTED
Cerevel Therapeutics Holdings, Inc. Common Stock
CERE
$7.29M 2.65%
225,000
-34,966
-13% -$1.23M
NVAX icon
14
PUT
Novavax
NVAX
$1.69B
$7.15M 2.6%
+50,000
New +$8.59M
ARYE
15
DELISTED
ARYA Sciences Acquisition Corp V Class A Ordinary Shares
ARYE
$6.81M 2.47%
702,500
– –
CYTK icon
16
Cytokinetics
CYTK
$10.1B
$6.63M 2.41%
145,552
+20,552
+16% +$793K
ACRS icon
17
Aclaris Therapeutics
ACRS
$908M
$5.82M 2.11%
400,000
+50,000
+14% +$758K
RPTX
18
DELISTED
Repare Therapeutics
RPTX
$5.73M 2.08%
+271,778
New +$6.4M
MDGL icon
19
Madrigal Pharmaceuticals
MDGL
$12.5B
$5.51M 2%
+65,000
New +$5.34M
NAUT icon
20
Nautilus Biotechnolgy
NAUT
$115M
$5.44M 1.97%
1,049,721
+74,721
+8% +$400K
ESTA icon
21
Establishment Labs
ESTA
$2.21B
$5.24M 1.9%
77,500
+17,500
+29% +$1.22M
CRIS icon
22
CALL
Curis
CRIS
$3.27M
$5M 1.81%
+2,625
New +$6.24M
CNTA
23
DELISTED
Centessa Pharmaceuticals
CNTA
$4.72M 1.71%
419,144
+215,961
+106% +$2.91M
XENE icon
24
Xenon Pharmaceuticals
XENE
$5.79B
$4.7M 1.71%
150,500
+100,500
+201% +$3M
BLU
25
DELISTED
BELLUS Health Inc.
BLU
$4.03M 1.46%
500,000
-32,030
-6% -$213K
1
2 3 4

Similar funds

BCP
BSN Capital Partners London, United Kingdom $2.21B AUM 22.85% 1-Year Est. Return
PCM
Parsons Capital Management Providence, Rhode Island $2.21B AUM 28.12% 1-Year Est. Return
IHL
Investment House LLC Redondo Beach, California $2.21B AUM 39.6% 1-Year Est. Return
1SB
1ST Source Bank South Bend, Indiana $2.21B AUM 28.75% 1-Year Est. Return
CCA
Checchi Capital Advisers Beverly Hills, California $2.22B AUM 23.18% 1-Year Est. Return
MYAM
Meiji Yasuda Asset Management Tokyo, Japan $2.22B AUM 32.92% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
LI
Leeward Investments Boston, Massachusetts $2.2B AUM 46.08% 1-Year Est. Return

Affinity Asset Advisors's Q4 2021 Portfolio in Review

As of Q4 2021, Affinity Asset Advisors held 87 positions worth $275M, down 30% from $396M the previous quarter. Its ten largest holdings account for 44% of the portfolio.

Affinity Asset Advisors's Q4 2021 filing shows 14 new, 18 increased, 10 reduced and 32 closed positions. Its largest new stake was Protagonist Therapeutics: 241,119 shares worth $8.25M. The largest sale was Ocular Therapeutix, an estimated $7.5M.

By sector, the portfolio is most concentrated in Healthcare at 74% of assets, up from 56% a quarter earlier, followed by Miscellaneous and Financials.

  • Affinity Asset Advisors's largest Q4 2021 buy was Protagonist Therapeutics: 241,119 shares worth $8.25M.
  • Affinity Asset Advisors added most to SpringWorks Therapeutics in Q4 2021, an estimated $11.4M increase.
  • Affinity Asset Advisors's biggest Q4 2021 reduction was BridgeBio Pharma, cutting an estimated $6.79M.
  • Affinity Asset Advisors fully exited Ocular Therapeutix in Q4 2021, selling an estimated $7.5M.
  • Affinity Asset Advisors's ten largest holdings make up 44% of its $275M portfolio in Q4 2021.
  • Affinity Asset Advisors opened 14 new positions and closed 32 in Q4 2021.
  • Affinity Asset Advisors's portfolio value fell 30% quarter-over-quarter to $275M.

Based on Affinity Asset Advisors's 13F filing for Q4 2021, filed 11 Feb 2022.